AbbVie, Genmab's lymphoma drug Epkinly snags FDA approval in heated blood cancer race

Big Pharma’s competition in the anti-CD20 bispecific space is taking shape, with the FDA on Friday approving what analysts view as a best-in-class blood cancer drug.

AbbVie and Genmab's epcoritamab has won accelerated approval to treat diffuse large B-cell lymphoma (DLBCL) after at least two lines of systemic therapy. The drug now bears the commercial moniker Epkinly.